Nls Pharmaceutics Ltd (NLSP)

Dec 19, 2024

NLS Pharmaceutics and Kadimastem eye January merger - Investing.com

Dec 19, 2024

Dec 19, 2024

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire

Dec 19, 2024

Dec 19, 2024

NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

Dec 19, 2024

Dec 18, 2024

NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India

Dec 18, 2024

Dec 12, 2024

NLS Pharmaceutics expects to close Kadimastem merger by end of January - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria

Dec 12, 2024

Dec 12, 2024

NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com Nigeria

Dec 12, 2024

Dec 11, 2024

NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger - Sleep Review

Dec 11, 2024

Dec 11, 2024

NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans - TipRanks

Dec 11, 2024

Dec 11, 2024

NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India

Dec 11, 2024

Dec 11, 2024

NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire

Dec 11, 2024

Dec 11, 2024

NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan

Dec 11, 2024

Dec 05, 2024

NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com

Dec 05, 2024

Dec 05, 2024

NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Canada

Dec 05, 2024

Dec 04, 2024

NLS Pharmaceutics Offers New Investment Opportunities - TipRanks

Dec 04, 2024

Dec 04, 2024

NLS Pharmaceutics sets terms for $1M private placement - Investing.com

Dec 04, 2024

Dec 04, 2024

NLS Pharmaceutics Secures $1M Premium-Priced Private Placement at 15% Above Market - StockTitan

Dec 04, 2024

Dec 04, 2024

NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online

Dec 04, 2024

Dec 04, 2024

NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 04, 2024

NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria

Dec 04, 2024

Dec 03, 2024

NLS Pharmaceutics reveals promising preclinical data - Investing.com India

Dec 03, 2024

Dec 03, 2024

NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com India

Dec 03, 2024

Dec 03, 2024

NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks

Dec 03, 2024

Dec 03, 2024

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire

Dec 03, 2024

Dec 03, 2024

NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan

Dec 03, 2024

Nov 18, 2024

Preclinical Program Investigates Potential of NLS’ Dual Orexin Agonists for Narcolepsy - Sleep Review

Nov 18, 2024

Nov 18, 2024

NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks

Nov 18, 2024

Nov 18, 2024

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire

Nov 18, 2024

Nov 18, 2024

NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks

Nov 15, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires Additional Shares in NLS Pharmac - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

Nov 14, 2024

Nov 14, 2024

NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com

Nov 14, 2024

Nov 14, 2024

500: Something went wrong - Investing.com India

Nov 14, 2024

Nov 12, 2024

Kadimastem Ltd. Faces Financial Uncertainty - TipRanks

Nov 12, 2024

Nov 06, 2024

NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks

Nov 06, 2024

Nov 05, 2024

What's Going On With NLS Pharmaceutics Shares Monday? - MSN

Nov 05, 2024

Nov 05, 2024

NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics and Kadimastem Announce Strategic Merger - TipRanks

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics, Kadimastem enter definitive merger agreement - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - MSN

Nov 05, 2024

Nov 05, 2024

NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com Canada

Nov 05, 2024

Nov 04, 2024

Definitive Merger Agreement Reached Between NLS and Kadimastem - Sleep Review

Nov 04, 2024

Nov 04, 2024

NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India

Nov 04, 2024

Nov 04, 2024

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - StreetInsider.com

Nov 04, 2024